Clinical Trial Update: BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors [EARLY_Phase 1]

View source ↗

Summary

A phase 1 clinical trial of BAFFR CAR-T therapy for relapsed/refractory B-cell tumors is not yet recruiting, sponsored by Guangzhou Bio-gene Technology Co., Ltd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Lymphoma

Drugs mentioned

• BAFFR CAR-T

Snippet

Sponsor: Guangzhou Bio-gene Technology Co., Ltd | Conditions: B Acute Lymphoblastic Leukemia/Lymphoma | EARLY_Phase 1 | Status: NOT_YET_RECRUITING